With a mean follow-up time of 78.2 months, patients with high HER-3 expression showed a comparable time to recurrence (TTR, P = 0.78) and cancer specific survival (CSS, P = 0.51) as compared to patients with low HER-3 expression (Fig. 5c, d). This evidence concerns the gene ERBB3 and cancer.